The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase ...